1. Search Result
Search Result
Results for "

cAMP

" in MedChemExpress (MCE) Product Catalog:

289

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

3

Biochemical Assay Reagents

67

Peptides

27

Natural
Products

10

Recombinant Proteins

6

Isotope-Labeled Compounds

15

Antibodies

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1511
    Cyclic AMP
    5+ Cited Publications

    Cyclic adenosine monophosphate; Adenosine cyclic 3', 5'-monophosphate; cAMP

    Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Cyclic AMP (Cyclic adenosine monophosphate), adenosine triphosphate derivative, is an intracellular signaling molecule responsible for directing cellular responses to extracellular signals. Cyclic AMP is an important second messenger in many biological processes .
    Cyclic AMP
  • HY-B1511A
    Cyclic AMP sodium
    5+ Cited Publications

    Cyclic adenosine monophosphate sodium; Adenosine cyclic 3', 5'-monophosphate sodium; cAMP sodium; Cyclic AMP sodium

    Biochemical Assay Reagents Neurological Disease Metabolic Disease Cancer
    Cyclic AMP (Cyclic adenosine monophosphate) sodium, adenosine triphosphate derivative, is an intracellular signaling molecule responsible for directing cellular responses to extracellular signals. Cyclic AMP sodium is an important second messenger in many biological processes .
    Cyclic AMP sodium
  • HY-131768

    Cholinesterase (ChE) Others
    2'-O-Succinyl-cAMP is a cAMP analog that can be covalently coupled to acetylcholinesterase. 2'-O-Succinyl-cAMP conjugate has been used as tracers in a classical heterogeneous competitive enzyme immunoassay allowing the determination of cAMP .
    2'-O-Succinyl-<em>cAMP</em>
  • HY-RS01870

    Small Interfering RNA (siRNA) Others
    CAMP Human Pre-designed siRNA Set A contains three designed siRNAs for CAMP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CAMP Human Pre-designed siRNA Set A
    CAMP Human Pre-designed siRNA Set A
  • HY-B1511S

    Cyclic adenosine monophosphate-13C5; Adenosine cyclic 3', 5'-monophosphate-13C5; cAMP-13C5

    Isotope-Labeled Compounds Others
    Cyclic AMP- 13C5 is a deuterated cyclic AMP.
    Cyclic AMP-13C5
  • HY-123396

    PKA Cancer
    8-Chloro-cAMP is a cAMP analogue that induces growth arrest, and modulates cAMP-dependent PKA activity. 8-Chloro-cAMP has anticancer activity .
    8-Chloro-<em>cAMP</em>
  • HY-134321

    Fluorescent Dye Others
    8-Azido-cAMP is a fluorescent cAMP analog, acting as the model target of detecting cAMP . 8-Azido-cAMP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
    8-Azido-<em>cAMP</em>
  • HY-B0764
    Bucladesine sodium
    20+ Cited Publications

    Dibutyryl cAMP sodium salt; DBcAMP sodium salt

    PKA Phosphodiesterase (PDE) Inflammation/Immunology
    Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective PKA activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing .
    Bucladesine sodium
  • HY-12306
    8-Bromo-cAMP sodium salt
    15+ Cited Publications

    8-Br-cAMP sodium salt

    PKA Apoptosis Cancer
    8-Bromo-cAMP sodium (8-Br-Camp) sodium salt, a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP sodium salt has anti-proliferative and apoptotic effects against cancer cells .
    8-Bromo-<em>cAMP</em> sodium salt
  • HY-12306A

    8-Br-cAMP

    PKA Apoptosis Cancer
    8-Bromo-cAMP (8-Br-Camp), a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP has anti-proliferative and apoptotic effects against cancer cells .
    8-Bromo-<em>cAMP</em>
  • HY-103322

    PKA
    6-Bnz-cAMP sodium salt is a cell-permeable cAMP analog. 6-Bnz-cAMP selectively activates cAMP-dependent PKA but not Epac signaling pathways .
    6-Bnz-<em>cAMP</em> sodium salt
  • HY-107543

    Ras Others
    8-CPT-2Me-cAMP sodium is a selective activator of exchange proteins activated by cAMP (Epac), the cAMP sensitive guanine nucleotide exchange factors (GEFs) for the small GTPases Rap1 and Rap2. 8-CPT-2Me-cAMP sodium activates Epac1 (EC50 = 2.2 μM), but not PKA (EC50> 10 μM) . 8-CPT-2Me-cAMP sodium stimulates Epac-mediated Ca 2+ release in pancreatic β-cells in vitro .
    8-CPT-2Me-<em>cAMP</em> sodium
  • HY-B0764A
    Bucladesine calcium
    20+ Cited Publications

    Dibutyryl cAMP calcium salt; DBcAMP calcium salt

    PKA Phosphodiesterase (PDE) Apoptosis Others
    Bucladesine calcium salt (Dibutyryl-cAMP calcium salt;DC2797 calcium salt) is a cell-permeable cyclic AMP (cAMP) analog and selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine calcium salt acts as a phosphodiesterase (PDE) inhibitor.
    Bucladesine calcium
  • HY-107544

    PKA Metabolic Disease
    8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates Epac-Rap signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating Epac from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with PKA pathway .
    8-pCPT-2'-O-Me-<em>cAMP</em>-AM
  • HY-131763

    2'-O-Monobutyryl cyclic AMP sodium

    Others Others
    2'-O-MB-cAMP (2'-O-Monobutyryl cyclic AM) sodium is an activatable proagent of Cyclic AMP (HY-B1511) .
    2'-O-MB-<em>cAMP</em> sodium
  • HY-120994

    PKA Neurological Disease Inflammation/Immunology
    Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .
    Rp-8-CPT-cAMPS sodium
  • HY-120994A

    PKA Neurological Disease Inflammation/Immunology
    Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .
    Rp-8-CPT-cAMPS
  • HY-100530A

    PKA Neurological Disease
    Rp-cAMPS, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS is resistant to hydrolysis by phosphodiesterases .
    Rp-cAMPS
  • HY-100530D
    Rp-cAMPS sodium salt
    2 Publications Verification

    PKA Neurological Disease
    Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS sodium salt is resistant to hydrolysis by phosphodiesterases .
    Rp-cAMPS sodium salt
  • HY-100530

    PKA Neurological Disease
    Rp-cAMPS triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS triethylammonium salt is resistant to hydrolysis by phosphodiesterases .
    Rp-cAMPS triethylammonium salt
  • HY-P3770

    PKC Others
    Phosphate acceptor peptide is a substrate for cAMP-dependent protein kinase (PKA). phosphate acceptor peptide is also a weak PKC inhibitor .
    Phosphate acceptor peptide
  • HY-P3786

    PKA PKC Cancer
    H-Arg-Gly-Tyr-Ala-Leu-Gly-OH is a competitive and CAMP dependent protein kinase inhibitor .
    H-Arg-Gly-Tyr-Ala-Leu-Gly-OH
  • HY-111673

    8-CPT-cAMP sodium; 8-(p-Chlorophenylthio)-cAMP sodium

    PKA Phosphodiesterase (PDE) Inflammation/Immunology
    8-CPT-Cyclic AMP (8-CPT-cAMP) sodium is a selective activator of cyclic AMP-dependent protein kinase (PKA). 8-CPT-Cyclic AMP sodium is also a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA) with an IC50 of 0.9 μM. 8-CPT-Cyclic AMP sodium also inhibits PDE III and PDE IV with IC50Epac and is a potent Epac activator .
    8-CPT-Cyclic AMP sodium
  • HY-D1187

    Fluorescent Dye Others
    2-Aza-ε-cAMP is a multifunctional dye. Dyes are important tools in biological experiments. They can help researchers observe and analyze cell structures, track biomolecules, evaluate cell functions, distinguish cell types, detect biomolecules, study tissue pathology and monitor microorganisms. Their applications range from basic scientific research to clinical A wide range of diagnostics. Dyes are also widely used in traditional fields such as textile dyeing, as well as in emerging fields such as functional textile processing, food pigments and dye-sensitized solar cells.
    2-Aza-ε-<em>cAMP</em>
  • HY-D1187A

    Fluorescent Dye Others
    2-Aza-ε-cAMP (sodium) is a multifunctional dye. Dyes are important tools in biological experiments. They can help researchers observe and analyze cell structures, track biomolecules, evaluate cell functions, distinguish cell types, detect biomolecules, study tissue pathology and monitor microorganisms. Their applications range from basic scientific research to clinical A wide range of diagnostics. Dyes are also widely used in traditional fields such as textile dyeing, as well as in emerging fields such as functional textile processing, food pigments and dye-sensitized solar cells.
    2-Aza-ε-<em>cAMP</em> sodium
  • HY-100530B

    PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS
  • HY-100530C

    PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS sodium salt
  • HY-110005

    PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS triethylamine
  • HY-P1325

    ((Cys31, Nva 34)-Neuropeptide Y (27-36))2

    Neuropeptide Y Receptor Neurological Disease
    BWX 46 (((Cys31, Nva 34)-Neuropeptide Y (27-36))2) is a selective Y5 receptor agonist with an IC50 value of 0.85 nM. BWX 46 can inhibit the synthesis of cAMP in Y5 cells .
    BWX 46
  • HY-N1189

    Syringaresinol Diacetate

    Others Cancer
    DL-Syringaresinol diacetate is a glucoside. DL-Syringaresinol inhibits cAMP phosphodiesterase and alleviation of stress .
    DL-Syringaresinol diacetate
  • HY-124151

    2'-AMP; Adenosine 2'-phosphate; AMP 2'-phosphate

    Adenosine Receptor Endogenous Metabolite Neurological Disease
    Adenosine-2'-monophosphate (2'-AMP) is converted by extracellular 2’,3'-CAMP. Adenosine-2'-monophosphate is further metabolized to extracellular adenosine (a mechanism called the extracellular 2’,3’-cAMP-adenosine pathway). Adenosine-2'-monophosphate inhibits LPS-induced TNF-α and CXCL10 production via A2A receptor activation .
    Adenosine-2'-monophosphate
  • HY-136172

    Ras Cardiovascular Disease Metabolic Disease Cancer
    ESI-08 is a potent and selective EPAC antagonist, which can completely inhibit both EPAC1 and EPAC2 (IC50 of 8.4 μM) activity. ESI-08 selectively blocks cAMP-induced EPAC activation, but does not inhibit cAMP-mediated PKA activation .
    ESI-08
  • HY-P3366

    XW003

    GCGR Metabolic Disease
    Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity .
    Ecnoglutide
  • HY-123782

    Neprilysin Metabolic Disease
    (Rac)-UK-414495 (example 7) is a potent neutral endopeptidase (NEP) inhibitor. (Rac)-UK-414495 causes potentiation of cAMP in the sexual genitalia of the female .
    (Rac)-UK-414495
  • HY-N3550

    Others Cancer
    Catalponol is a naphthoquinone derivative. Catalponol enhances dopamine biosynthesis by inducing tyrosine hydroxylase activity. Catalponol also increases the levels of cAMP and tyrosine hydroxylase phosphorylation in PC12 cells .
    Catalponol
  • HY-158180

    Adenosine Receptor Inflammation/Immunology
    A3AR agonist 4 is an A3 adenosine receptor (A3AR) agonist (Ki: 1.24 nM for hA3AR). A3AR agonist 4 inhibits cAMP production with an EC50 of 0.17 nM. A3AR agonist 4 can be used for research of inflammation and pain .
    A3AR agonist 4
  • HY-141495
    (Rac)-Razpipadon
    1 Publications Verification

    PW0464

    Dopamine Receptor Neurological Disease
    PW0464, a nanomolar potent complete G protein biased ligand, is a noncatechol D1R agonist, with an EC50 of 5.8 nM (Gs-cAMP) .
    (Rac)-Razpipadon
  • HY-100927

    Ro 20-174

    Phosphodiesterase (PDE) Neurological Disease
    Ro 20-1724 (Ro 20-174) is a potent inhibitor of cAMP-specific phosphodiesterase (PDE4/PDE IV) with a Ki of 1930 nM. Neuroprotective effect .
    Ro 20-1724
  • HY-103180

    Adenosine Receptor Neurological Disease
    2'-MeCCPA is a potent and selective A1 adenosine receptors (A1AR) agonist. 2'-MeCCPA efficiently inhibits cAMP modulation in both direct pathway medium spiny neurons (dMSNs) and indirect pathway medium spiny neurons (iMSNs) .
    2'-MeCCPA
  • HY-117656
    ESI-05
    3 Publications Verification

    NSC 116966

    Acyltransferase Neurological Disease Metabolic Disease
    ESI-05 is a specific exchange proteins directly activated by cAMP 2 (EPAC2) inhibitor. ESI-05 inhibits cAMP-mediated EPAC2 GEF activity with an IC50 of 0.43 μM. ESI-05 can be used for the research of diabetes, insulin secretion and neurological disorders .
    ESI-05
  • HY-P2197

    Apelin Receptor (APJ) Arrestin Inflammation/Immunology
    ELA-11(human), a peptide, is a full agonist of human apelin receptor, with a pKi of 7.85. ELA-11(human) completely inhibits Forskolin-induced cAMP production and stimulates β-arrestin recruitment .
    ELA-11(human)
  • HY-P2249

    Arrestin Apelin Receptor (APJ) Cardiovascular Disease
    ELA-21 (human) is an apelin receptor agonist with a pKi of 8.52. ELA-21 (human) completely inhibits Forskolin-induced cAMP production and stimulates β-arrestin recruitment with subnanomolar potencies. ELA-21 (human) is an agonist in G-protein-dependent and -independent pathways .
    ELA-21 (human)
  • HY-158181

    Adenosine Receptor Inflammation/Immunology
    A3AR agonist 5 (Compound 6b) is a A3 adenosine receptor (A3AR) activator, with EC50 and Ki values of 0.14 nM and 6.36 nM for cAMP and hA3, respectively. A3AR agonist 5 can be used in pain and inflammatory research .
    A3AR agonist 5
  • HY-158179

    Adenosine Receptor Neurological Disease
    A3AR agonist 3 (Compound 15A) is a A3 adenosine receptor (A3AR) agonist, with Ki and EC50 values of 2.27 and 0.20 nM for hA3 and cAMP, respectivelly. A3AR agonist 3 can e used for the research of neuroinflammation .
    A3AR agonist 3
  • HY-131032

    Adenosine Receptor Others
    KI-7 is an A2B adenosine receptor positive allosteric modulator. KI-7 potentiates the cAMP accumulation induced by the non-selective A2B adenosine receptor agonist NECA (EC50=445.8 nM). KI-7 also potentiates the cAMP accumulation induced by the selective A2B adenosine receptor agonist BAY 60-6583 as well as by adenosine with EC50s of 2390 nM and 2550 nM, respectively .
    KI-7
  • HY-N2168

    (+)-Pinoresinol 4-O-β-D-glucopyranoside

    Others Cardiovascular Disease
    Pinoresinol 4-O-β-D-glucopyranoside ((+)-Pinoresinol 4-O-β-D-glucopyranoside) is the major active furofuran type lignans in Fructus Forsythiae. Pinoresinol 4-O-β-D-glucopyranoside shows antioxidant, blood pressure reducing, and cyclic adenosine monophosphate (cAMP) phosphodiesterase inhibitory effects .
    Pinoresinol 4-O-β-D-glucopyranoside
  • HY-19755

    Prostaglandin Receptor Inflammation/Immunology
    S-5751 is an orally active prostaglandin DP receptor antagonist. S-5751 inhibits cAMP generation in platelet-rich plasma induced by PGD2 with IC50 0.12 μM. S-5751 has anti-inflammatory activity. S-5751 can be used in asthma research .
    S-5751
  • HY-N2658

    Phosphodiesterase (PDE) Others
    5,7-Diacetoxy-8-methoxyflavone is a natural product that could come from scutellaria genus plants. 5,7-Diacetoxy-8-methoxyflavone has inhibitory activity for cAMP phosphodiesterase .
    5,7-Diacetoxy-8-methoxyflavone
  • HY-134266
    8-Bromo-AMP
    1 Publications Verification

    8-Bromoadenosine 5'-monophosphate; 8-Bromoadenylic acid

    Others Cardiovascular Disease
    8-Bromo-AMP (8-Bromoadenosine 5'-monophosphate) is a membrane permeable cAMP analogue. 8-Bromo-AMP can improve the ability of the heart to recover from ischemia and reperfusion by increasing the levels of ATP, ADP, and total adenine nucleotides .
    8-Bromo-AMP
  • HY-B0392

    (+)-Rolipram; (S)-Rolipram

    Phosphodiesterase (PDE) Apoptosis Neurological Disease Inflammation/Immunology Cancer
    (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic AMP(cAMP)-specific phosphodiesterase 4 (PDE4) inhibitor, with an IC50 of 1100 nM. (S)-(+)-Rolipram can suppresse tumor necrosis factor-alpha (TNFα) production by human mononuclear cells .
    (S)-(+)-Rolipram

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: